{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:26:54Z","timestamp":1789590414772,"version":"build-2803163510"},"reference-count":59,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Psoriatic arthritis and ankylosing spondylitis are chronic inflammatory diseases that can cause significant disability. The commercialization of the first tumour necrosis factor (TNF) inhibitors led to a radical improvement of the quality of life of people affected by these conditions; however, response was not universal, highlighting the need for alternative therapeutic targets. Secukinumab is a monoclonal interleukin (IL)-17A inhibitor which has been proven efficacious for psoriatic arthritis and ankylosing spondylitis in recent clinical trials. Dactylitis, enthesitis, skin and nails are some of the domains in which the inhibition of IL-17 has shown significant improvements apart from the joints. Its safety profile and satisfactory medium- to long-term outcome data are some of the aspects suggesting its potential impact in treatment protocols in the short term.<\/jats:p>","DOI":"10.1177\/1759720x18787766","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T01:42:35Z","timestamp":1536284555000},"page":"169-180","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis"],"prefix":"10.1177","volume":"10","author":[{"given":"Leticia","family":"Garcia-Montoya","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"LIRMM, University of Leeds, Second floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"bibr1-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"bibr2-1759720X18787766","doi-asserted-by":"crossref","unstructured":"Bakland G, Nossent HC. Epidemiology of spondyloarthritis: a review. Curr Rheumatol Rep [Internet] 2013; 15: 351. http:\/\/link.springer.com\/10.1007\/s11926-013-0351-1 (2013, accessed 25 January 2018).","DOI":"10.1007\/s11926-013-0351-1"},{"key":"bibr3-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v2.i12.07"},{"key":"bibr4-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/art.38050"},{"key":"bibr5-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"bibr6-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"bibr7-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.12.003"},{"key":"bibr8-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000069"},{"key":"bibr9-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0557-4"},{"key":"bibr10-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051914-021944"},{"key":"bibr11-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3387-x"},{"key":"bibr12-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.183"},{"key":"bibr13-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206323"},{"key":"bibr14-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/art.30593"},{"key":"bibr15-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002653"},{"key":"bibr16-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1038\/ni1254"},{"key":"bibr17-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.12.004"},{"key":"bibr18-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1995"},{"key":"bibr19-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.11.6173"},{"key":"bibr20-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1084284"},{"key":"bibr21-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"bibr22-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030896"},{"key":"bibr23-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/art.39464"},{"key":"bibr24-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5703"},{"key":"bibr25-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"bibr26-1759720X18787766","doi-asserted-by":"crossref","unstructured":"Cheung PP. Anti-IL17A in axial spondyloarthritis\u2014where are we at? Front Med [Internet] 2017; 4. http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00001\/full (2017, accessed 8 December 2017).","DOI":"10.3389\/fmed.2017.00001"},{"key":"bibr27-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker194"},{"key":"bibr28-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0076-0"},{"key":"bibr29-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"bibr30-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"bibr31-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23111"},{"key":"bibr32-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"bibr33-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"bibr34-1759720X18787766","doi-asserted-by":"crossref","unstructured":"Nash P, Mease PJ, McInnes IB, et al, Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018; 20(1): 47.","DOI":"10.1186\/s13075-018-1551-x"},{"key":"bibr35-1759720X18787766","unstructured":"k. Abram AK. Arthritis: primary results through 52 weeks from a phae-3 randomized placebo-controlled study (FUTURE 4). Abstract at PANLAR congress 2018."},{"key":"bibr36-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"bibr37-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"bibr38-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"bibr39-1759720X18787766","author":"Baraliakos X","journal-title":"Clin Exp Rheumatol"},{"key":"bibr40-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/art.39805"},{"key":"bibr41-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"bibr42-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"bibr43-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23233"},{"key":"bibr44-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/art.20775"},{"key":"bibr45-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1002\/art.39685"},{"key":"bibr46-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207544"},{"key":"bibr47-1759720X18787766","first-page":"3939","volume":"67","author":"Braun J BX","year":"2015","journal-title":"Abstr No 6L"},{"key":"bibr48-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"bibr49-1759720X18787766","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"Haroon N","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"bibr50-1759720X18787766","first-page":"50","volume":"36","author":"Baraliakos X.","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"bibr51-1759720X18787766","unstructured":"COSENTYX \u00ae (secukinumab). http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003729\/human_med_001832.jsp&mid=WC0b01ac058001d124 (accessed 25 January 2018)."},{"key":"bibr52-1759720X18787766","unstructured":"COSENTYX \u00ae (secukinumab). New Jersey: Novartis Pharmaceuticals Corporation, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125504s001s002lbl.pdf (2015, accessed 25 January 2018)."},{"key":"bibr53-1759720X18787766","unstructured":"Novartis Europharm Limited. Cosentyx: summary of product characteristics, http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003729\/human_med_001832.jsp&mid=WC0b01ac08001d124 (2016, accessed 25 January 2018)."},{"key":"bibr54-1759720X18787766","unstructured":"Novartis. COSENTYX (secukinumab) injection, for subcutaneous use: prescribing information, http:\/\/www.accessdata.Fda.gov (2016, accessed 25 January 2018)."},{"key":"bibr55-1759720X18787766","unstructured":"Drugs@FDA: FDA Approved Drug Products. Novartis Pharms Corp. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=125504 (accessed 25 January 2018)."},{"key":"bibr56-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"bibr57-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208466"},{"key":"bibr58-1759720X18787766","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"Coates LC","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"bibr59-1759720X18787766","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170144"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X18787766","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X18787766","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X18787766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:36:14Z","timestamp":1777588574000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X18787766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1177\/1759720X18787766"],"URL":"https:\/\/doi.org\/10.1177\/1759720x18787766","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}